Symbols / PRTC Stock $18.34 +4.74% PureTech Health plc

Healthcare • Biotechnology • United States • NGM
PRTC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Robert Lyne J.D., L.L.B.
Exch · Country NGM · United States
Market Cap 446.43M
Enterprise Value 4.06B
Income -109.74M
Sales 4.66M
FCF (ttm) -98.29M
Book/sh 13.16
Cash/sh 1.22
Employees —
Insider 10d —
IPO Nov 16, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 10.67
Forward P/E -36.68
PEG —
P/S 95.82
P/B 1.39
P/C —
EV/EBITDA -42.67
EV/Sales 871.61
Quick Ratio 6.41
Current Ratio 6.59
Debt/Eq 66.49
LT Debt/Eq —
EPS (ttm) -4.60
EPS next Y -0.50
EPS Growth —
Revenue Growth -38.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-29
Earnings (prior) 2026-04-29
ROA -10.83%
ROE -30.85%
ROIC —
Gross Margin 100.00%
Oper. Margin -18.02%
Profit Margin 0.00%
Shs Outstand 24.34M
Shs Float 165.22M
Insider Own 0.00%
Instit Own 0.39%
Short Float 0.12%
Short Ratio 3.94
Short Interest 24.52K
52W High 19.92
vs 52W High -7.93%
52W Low 14.50
vs 52W Low 26.48%
Beta —
Impl. Vol. —
Rel Volume 0.35
Avg Volume 8.45K
Volume 2.93K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $17.51
Price $18.34
Change 4.74%
About

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$18.34
Latest analyst target
3. DCF / Fair value
$-72.68
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.34
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2022-08-25 main Piper Sandler — → Overweight $44
2022-08-09 main SVB Leerink — → Outperform $70
2022-06-15 main SVB Leerink — → Outperform $66
2022-01-07 main SVB Leerink — → Outperform $70
2021-08-25 main SVB Leerink — → Outperform $76
2021-01-15 init SVB Leerink — → Outperform $70
News
RSS: Latest PRTC news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
4.66
+7.97%
4.32
+475.33%
0.75
-64.11%
2.09
Operating Revenue
4.66
+7.97%
4.32
+475.33%
0.75
-64.11%
2.09
Operating Expense
103.18
-26.51%
140.41
-4.45%
146.95
-26.49%
199.90
Research And Development
45.74
-15.73%
54.28
-26.38%
73.73
-33.75%
111.29
Selling General And Administration
20.65
-24.87%
27.49
+9.18%
25.18
-20.32%
31.60
General And Administrative Expense
20.65
-24.87%
27.49
+9.18%
25.18
-20.32%
31.60
Other Operating Expenses
1.03
-30.82%
1.50
-5.91%
1.59
-30.45%
2.29
Total Expenses
103.18
-26.51%
140.41
-4.45%
146.95
-26.49%
199.90
Operating Income
-98.53
+27.61%
-136.09
+6.91%
-146.20
+26.09%
-197.81
Total Operating Income As Reported
-98.53
+27.60%
-136.09
+6.91%
-146.20
+26.09%
-197.81
EBITDA
-61.80
-265.32%
37.38
+311.42%
-17.68
+77.88%
-79.94
Normalized EBITDA
-102.36
+2.09%
-104.54
+34.64%
-159.94
+21.10%
-202.72
Reconciled Depreciation
3.35
-6.24%
3.57
-27.61%
4.93
-44.53%
8.89
EBIT
-65.15
-292.69%
33.81
+249.51%
-22.61
+74.54%
-88.83
Total Unusual Items
40.56
-71.42%
141.93
-0.24%
142.26
+15.86%
122.78
Total Unusual Items Excluding Goodwill
40.56
-71.42%
141.93
-0.24%
142.26
+15.86%
122.78
Special Income Charges
1.70
-98.88%
152.28
+146.46%
61.79
+31.24%
47.08
Other Special Charges
-1.70
+98.88%
-152.28
-146.46%
-61.79
-11.39%
-55.47
Impairment Of Capital Assets
—
—
—
—
Write Off
—
0.00
0.00
-100.00%
8.39
Net Income
-109.74
-305.08%
53.51
+181.45%
-65.70
-30.47%
-50.35
Pretax Income
-110.93
-566.59%
23.77
+165.85%
-36.10
+61.09%
-92.78
Net Non Operating Interest Income Expense
-32.73
-359.10%
12.63
+400.48%
2.52
+36.73%
1.85
Interest Expense Non Operating
45.78
+356.08%
10.04
-25.59%
13.49
+241.21%
3.95
Net Interest Income
-32.73
-359.10%
12.63
+400.48%
2.52
+36.73%
1.85
Interest Expense
45.78
+356.08%
10.04
-25.59%
13.49
+241.21%
3.95
Interest Income Non Operating
13.05
-42.44%
22.67
+41.58%
16.01
+176.12%
5.80
Interest Income
13.05
-42.44%
22.67
+41.58%
16.01
+176.12%
5.80
Other Non Operating Income Expenses
1.33
+38.50%
0.96
+205.84%
-0.91
-111.17%
8.13
Tax Provision
-0.84
+78.99%
-4.01
-113.13%
30.52
+154.78%
-55.72
Tax Rate For Calcs
0.00
-96.39%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.31
-98.97%
29.80
-0.24%
29.87
+15.86%
25.78
Net Income Including Noncontrolling Interests
-110.08
-496.24%
27.78
+141.70%
-66.63
-79.76%
-37.06
Net Income From Continuing Operation Net Minority Interest
-109.74
-305.08%
53.51
+181.45%
-65.70
-30.47%
-50.35
Net Income From Continuing And Discontinued Operation
-109.74
-305.08%
53.51
+181.45%
-65.70
-30.47%
-50.35
Net Income Continuous Operations
-110.08
-496.24%
27.78
+141.70%
-66.63
-79.76%
-37.06
Minority Interests
0.34
-98.66%
25.73
+2663.48%
0.93
+107.01%
-13.29
Normalized Income
-149.99
-155.91%
-58.61
+67.09%
-178.08
-20.86%
-147.35
Net Income Common Stockholders
-109.74
-305.08%
53.51
+181.45%
-65.70
-30.47%
-50.35
Otherunder Preferred Stock Dividend
0.00
0.00
0.00
0.00
Diluted EPS
-4.60
-319.05%
2.10
+187.50%
-2.40
-33.33%
-1.80
Basic EPS
-4.60
-319.05%
2.10
+187.50%
-2.40
-33.33%
-1.80
Basic Average Shares
24.08
-5.37%
25.45
-7.91%
27.63
-2.97%
28.48
Diluted Average Shares
24.08
-5.95%
25.60
-7.34%
27.63
-2.97%
28.48
Diluted NI Availto Com Stockholders
-109.74
-305.08%
53.51
+181.45%
-65.70
-30.47%
-50.35
Amortization
1.76
+0.00%
1.76
-10.86%
1.98
-35.07%
3.05
Depreciation And Amortization In Income Statement
3.35
-6.22%
3.57
-27.62%
4.93
-44.52%
8.89
Depreciation Income Statement
1.58
-12.29%
1.81
-38.85%
2.96
-49.44%
5.84
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
534.71
-11.27%
602.63
-13.16%
693.97
-1.23%
702.65
Current Assets
305.02
-21.03%
386.26
+11.25%
347.20
-10.10%
386.19
Cash Cash Equivalents And Short Term Investments
277.30
-24.50%
367.31
+12.28%
327.14
-6.56%
350.10
Cash And Cash Equivalents
252.47
-10.04%
280.64
+46.87%
191.08
+27.50%
149.87
Other Short Term Investments
24.83
-71.35%
86.67
-36.30%
136.06
-32.05%
200.23
Accounts Receivable
1.76
+15.51%
1.52
-35.94%
2.38
-79.98%
11.87
Other Receivables
11.42
+0.32%
11.38
—
—
Taxes Receivable
6.37
0.00
-100.00%
11.75
+16.99%
10.04
Prepaid Assets
6.58
+49.32%
4.40
+2.20%
4.31
-62.91%
11.62
Restricted Cash
1.60
-2.80%
1.64
+0.86%
1.63
-23.35%
2.12
Other Current Assets
—
—
-0.00
+0.00%
-0.00
Total Non Current Assets
229.69
+6.15%
216.38
-37.60%
346.77
+9.58%
316.45
Net PPE
11.50
-23.99%
15.13
-21.86%
19.36
-48.01%
37.24
Gross PPE
24.64
-11.92%
27.98
-13.50%
32.34
-43.57%
57.32
Accumulated Depreciation
-13.14
-2.29%
-12.85
+1.04%
-12.98
+35.35%
-20.08
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
15.16
+0.00%
15.16
+0.00%
15.16
-36.72%
23.96
Machinery Furniture Equipment
1.34
-16.23%
1.60
-19.46%
1.99
-32.09%
2.93
Construction In Progress
0.00
0.00
-100.00%
0.00
-99.96%
2.80
Other Properties
8.13
-27.44%
11.21
-26.20%
15.19
-45.01%
27.62
Goodwill And Other Intangible Assets
0.60
+0.00%
0.60
-33.66%
0.91
+9.03%
0.83
Other Intangible Assets
0.60
+0.00%
0.60
-33.66%
0.91
+9.03%
0.83
Long Term Equity Investment
0.00
-100.00%
2.40
-24.74%
3.19
-65.18%
9.15
Other Non Current Assets
0.17
-65.13%
0.48
-45.79%
0.88
+8680.00%
0.01
Total Liabilities Net Minority Interest
229.03
+17.63%
194.70
-17.41%
235.74
+52.03%
155.06
Current Liabilities
46.31
+11.89%
41.39
-19.43%
51.37
-46.98%
96.89
Payables
4.29
-34.10%
6.51
-55.51%
14.64
-48.66%
28.52
Accounts Payable
3.07
-44.40%
5.52
-62.27%
14.64
-44.77%
26.50
Other Payable
0.01
-98.36%
0.92
+30466.67%
0.00
-99.85%
1.96
Pensionand Other Post Retirement Benefit Plans Current
1.83
-2.56%
1.88
+46.37%
1.28
-29.03%
1.80
Total Tax Payable
1.21
+1510.67%
0.07
0.00
-100.00%
0.06
Current Debt And Capital Lease Obligation
8.50
+10.53%
7.69
+8.42%
7.09
-43.13%
12.47
Current Debt
4.92
+19.58%
4.11
+11.14%
3.70
-50.69%
7.50
Current Capital Lease Obligation
3.58
+0.14%
3.58
+5.45%
3.39
-31.74%
4.97
Other Current Liabilities
13.42
+103.15%
6.60
+3807.69%
0.17
-99.38%
27.34
Total Non Current Liabilities Net Minority Interest
182.72
+19.18%
153.31
-16.85%
184.37
+216.94%
58.17
Long Term Debt And Capital Lease Obligation
11.09
-24.43%
14.67
-19.61%
18.25
-46.95%
34.40
Long Term Debt
—
—
0.00
-100.00%
10.24
Long Term Capital Lease Obligation
11.09
-24.43%
14.67
-19.61%
18.25
-24.45%
24.16
Non Current Pension And Other Postretirement Benefit Plans
1.22
-34.61%
1.86
-46.84%
3.50
-15.19%
4.13
Non Current Deferred Taxes Liabilities
—
0.00
-100.00%
52.46
+167.05%
19.64
Other Non Current Liabilities
170.42
+24.59%
136.78
+24.17%
110.16
+11015800.00%
0.00
Stockholders Equity
312.07
-24.75%
414.71
-10.64%
464.07
-14.41%
542.22
Common Stock Equity
312.07
-24.75%
414.71
-10.64%
464.07
-14.41%
542.22
Capital Stock
4.86
+0.00%
4.86
-11.01%
5.46
+0.11%
5.46
Common Stock
4.86
+0.00%
4.86
-11.01%
5.46
+0.11%
5.46
Share Issued
257.93
+0.00%
257.93
-10.90%
289.47
+0.11%
289.16
Ordinary Shares Number
241.68
+0.95%
239.42
-11.93%
271.85
-2.41%
278.57
Treasury Shares Number
16.24
-12.23%
18.51
+5.06%
17.61
+66.25%
10.60
Additional Paid In Capital
290.26
+0.00%
290.26
+0.00%
290.26
+0.22%
289.62
Retained Earnings
-77.23
-337.74%
32.49
-61.24%
83.82
-43.94%
149.52
Treasury Stock
41.15
-12.18%
46.86
+5.02%
44.63
+68.45%
26.49
Minority Interest
-6.40
+5.57%
-6.77
-16.09%
-5.83
-208.68%
5.37
Total Equity Gross Minority Interest
305.68
-25.07%
407.93
-10.98%
458.23
-16.32%
547.59
Total Capitalization
312.07
-24.75%
414.71
-10.64%
464.07
-16.00%
552.46
Working Capital
258.71
-24.98%
344.87
+16.58%
295.83
+2.26%
289.31
Invested Capital
316.99
-24.31%
418.82
-10.46%
467.76
-16.47%
559.97
Total Debt
19.59
-12.41%
22.36
-11.77%
25.34
-45.93%
46.87
Capital Lease Obligations
14.67
-19.61%
18.25
-15.68%
21.64
-25.69%
29.13
Net Tangible Assets
311.47
-24.78%
414.11
-10.59%
463.16
-14.45%
541.39
Tangible Book Value
311.47
-24.78%
414.11
-10.59%
463.16
-14.45%
541.39
Available For Sale Securities
217.43
+13.58%
191.43
-39.77%
317.84
+26.18%
251.89
Financial Assets Designatedas Fair Value Through Profitor Loss Total
—
191.43
-39.77%
317.84
+26.18%
251.89
Investmentin Financial Assets
217.43
+13.58%
191.43
-39.77%
317.84
+26.18%
251.89
Investmentsin Associatesat Cost
0.00
-100.00%
2.40
-24.74%
3.19
-65.18%
9.15
Other Equity Interest
—
0.00
+200.00%
-0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-85.13
+36.64%
-134.37
-26.86%
-105.92
+40.76%
-178.79
Net Income From Continuing Operations
-110.08
-496.24%
27.78
+141.70%
-66.63
-79.76%
-37.06
Depreciation
1.58
-12.34%
1.81
-38.83%
2.95
-66.78%
8.89
Amortization Cash Flow
1.76
+0.00%
1.76
-10.86%
1.98
-35.07%
3.05
Depreciation And Amortization
3.35
-6.24%
3.57
-27.61%
4.93
-44.53%
8.89
Other Non Cash Items
32.73
+359.10%
-12.63
-400.48%
-2.52
-36.73%
-1.85
Stock Based Compensation
8.22
-64.02%
22.85
+417.55%
4.42
-69.96%
14.70
Deferred Tax
-0.84
+78.99%
-4.01
-113.13%
30.52
+154.78%
-55.72
Gain Loss On Investment Securities
-35.33
-1178.96%
-2.76
+94.73%
-52.38
+37.44%
-83.72
Net Foreign Currency Exchange Gain Loss
0.01
-76.00%
0.03
-73.40%
0.09
+771.43%
-0.01
Gain Loss On Sale Of PPE
—
—
—
0.14
Change In Working Capital
-3.12
+69.49%
-10.24
-158.43%
17.52
+10.05%
15.92
Change In Receivables
-0.24
-137.52%
0.63
-93.55%
9.75
+226.07%
-7.73
Change In Prepaid Assets
-1.86
-47.54%
-1.26
-144.53%
2.83
+428.77%
-0.86
Change In Payable
-1.02
+89.43%
-9.70
-352.21%
3.84
-82.55%
22.03
Change In Other Current Assets
0.00
-100.00%
0.09
-91.57%
1.09
-56.04%
2.48
Change In Other Current Liabilities
—
—
—
—
Investing Cash Flow
63.29
-73.73%
240.89
+249.16%
68.99
+164.34%
-107.22
Net PPE Purchase And Sale
0.26
+7.79%
0.24
-69.31%
0.80
+136.53%
-2.18
Purchase Of PPE
-0.01
+45.45%
-0.01
+84.29%
-0.07
+96.78%
-2.18
Sale Of PPE
0.27
+5.49%
0.26
-70.52%
0.86
0.00
Capital Expenditure
-0.01
+45.45%
-0.01
+95.51%
-0.24
+88.74%
-2.18
Net Investment Purchase And Sale
63.86
-81.57%
346.61
+321.90%
82.16
+196.63%
-85.02
Purchase Of Investment
-84.20
+72.80%
-309.60
-58.19%
-195.71
+27.17%
-268.73
Sale Of Investment
148.06
-77.44%
656.22
+136.16%
277.87
+51.25%
183.71
Net Business Purchase And Sale
-0.89
+99.16%
-105.97
-668.79%
-13.78
+32.56%
-20.44
Purchase Of Business
-0.89
+99.16%
-105.97
-668.79%
-13.78
+32.56%
-20.44
Gain Loss On Sale Of Business
-1.70
+98.88%
-152.01
-146.02%
-61.79
-11.39%
-55.47
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-0.17
0.00
Purchase Of Intangibles
0.00
0.00
+100.00%
-0.17
0.00
Net Other Investing Changes
0.05
—
—
0.42
Financing Cash Flow
-6.33
+62.68%
-16.96
-121.70%
78.14
+361.98%
-29.83
Net Issuance Payments Of Debt
—
0.00
0.00
-100.00%
0.39
Issuance Of Debt
—
0.00
0.00
-100.00%
0.39
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
0.00
0.00
-100.00%
0.39
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
0.00
0.00
-100.00%
0.39
Short Term Debt Issuance
—
—
0.00
-100.00%
0.39
Net Short Term Debt Issuance
—
—
0.00
-100.00%
0.39
Net Common Stock Issuance
-1.95
+98.17%
-106.66
-476.66%
-18.50
+29.29%
-26.16
Common Stock Payments
-2.05
+98.09%
-107.56
-447.37%
-19.65
+25.83%
-26.49
Repurchase Of Capital Stock
-2.05
+98.09%
-107.56
-447.37%
-19.65
+25.83%
-26.49
Net Other Financing Charges
-0.80
-100.86%
93.10
-6.88%
99.98
+285745.71%
-0.04
Changes In Cash
-28.17
-131.45%
89.56
+117.30%
41.22
+113.05%
-315.84
Effect Of Exchange Rate Changes
—
—
—
—
Beginning Cash Position
280.64
+46.87%
191.08
+27.50%
149.87
-67.82%
465.71
End Cash Position
252.47
-10.04%
280.64
+46.87%
191.08
+27.50%
149.87
Free Cash Flow
-85.14
+36.64%
-134.38
-26.58%
-106.16
+41.34%
-180.97
Common Stock Issuance
0.11
-88.16%
0.90
-22.38%
1.15
+247.29%
0.33
Interest Paid CFO
-4.52
-249.11%
-1.29
+23.87%
-1.70
+49.47%
-3.37
Interest Received CFO
13.62
-42.15%
23.55
+62.91%
14.45
+317.75%
3.46
Issuance Of Capital Stock
0.11
-88.16%
0.90
-22.38%
1.15
+247.29%
0.33
Other Cash Adjustment Outside Changein Cash
—
-0.00
—
—
Taxes Refund Paid
-5.50
+85.49%
-37.91
-25175.33%
-0.15
+99.28%
-20.70
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category